{"disease":{"id":"eosinophilic-asthma","name":"Eosinophilic asthma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"benralizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fasenra","generic_name":"BENRALIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interleukin-5 receptor subunit alpha","drug_class":"Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"1800","mechanism":"Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction."},{"drug_id":"mepolizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nucala","generic_name":"MEPOLIZUMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":10,"revenue":"1600","mechanism":"Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils."},{"drug_id":"prednisolone","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nucala","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nucala","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"reslizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cinqair","generic_name":"RESLIZUMAB","company_name":"Teva Respiratory Llc","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Cinqair works by blocking the action of interleukin-5, a protein that promotes the production of eosinophils, which contribute to inflammation in the airways."},{"drug_id":"diethylcarbamazine","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caricide","generic_name":"DIETHYLCARBAMAZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase","drug_class":"Anthelmintic","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05763121","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1061,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT03696914","title":"Intense Airway Eosinophilia in Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":918,"lead_sponsor_name":"Laval University","has_results":false},{"nct_id":"NCT05813288","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":654,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT04046939","title":"Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"Knopp Biosciences","has_results":true},{"nct_id":"NCT06388889","title":"Phase III Long-Term Extension Study With Dexpramipexole","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":509,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT06465485","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":504,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06750289","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07214753","title":"A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":335,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04538937","title":"Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT05180357","title":"RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04456270","title":"Asthma Control in a Dutch Primary Care Population","phase":"","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"General Practitioners Research Institute","has_results":false},{"nct_id":"NCT04159519","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03833141","title":"Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05440656","title":"A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04680611","title":"Severe Asthma, MepolizumaB and Affect: SAMBA Study","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT04671446","title":"Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Queen Mary University of London","has_results":true},{"nct_id":"NCT03563521","title":"Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"TC Erciyes University","has_results":false},{"nct_id":"NCT05288504","title":"A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Avalo Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07343661","title":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Azienda Ospedaliero Universitaria di Cagliari","has_results":false},{"nct_id":"NCT05270278","title":"Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Value Outcomes Ltd.","has_results":false},{"nct_id":"NCT05365841","title":"Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).","phase":"","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"University of Crete","has_results":false},{"nct_id":"NCT04542902","title":"Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Lithuanian University of Health Sciences","has_results":false},{"nct_id":"NCT03907137","title":"Real World Study With Benralizumab in Severe Asthma in Switzerland","phase":"","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04187976","title":"Eosinophils Endotypes in Chronic Airway Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT04674137","title":"XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Chemlmmune Therapeutics LLC","has_results":false},{"nct_id":"NCT04445038","title":"Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03739320","title":"A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sotiria General Hospital","has_results":false},{"nct_id":"NCT06302959","title":"Clock Proteins as Prognostic Markers","phase":"","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT04765722","title":"Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"McMaster University","has_results":true},{"nct_id":"NCT04612556","title":"Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)","phase":"","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT05985694","title":"AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Advagene Biopharma Co. Ltd.","has_results":false},{"nct_id":"NCT06069310","title":"Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National and Kapodistrian University of Athens","has_results":false},{"nct_id":"NCT04641741","title":"Effect of Mepolizumab on Severe Eosinophilic Asthma","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Hospital Clinico Universitario de Santiago","has_results":false},{"nct_id":"NCT04126499","title":"Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03469934","title":"Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"AnaptysBio, Inc.","has_results":true},{"nct_id":"NCT05002621","title":"Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03470311","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03652376","title":"Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University of Rostock","has_results":false},{"nct_id":"NCT05063981","title":"Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Istituti Clinici Scientifici Maugeri SpA","has_results":false},{"nct_id":"NCT05271526","title":"Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)","phase":"","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}